Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial

Maignan, Christine Le; Desablens, B; Delwail, Vincent; Dib, Mahmoud; Berthou, Christian; Vigier, Magda; Ghandour, C; Atmani, Saïd; Casassus, Philippe; Maisonneuve, Hervé; Mevel, A. Le; Traulle, Catherine; Bernard, Marc; Brière, Josette; Colonna, P; Andrieu, Jean‐Marie

doi:10.1182/blood-2003-05-1611

Cited by 22 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were classified in CS IA to IVB according to the Ann Arbor criteria. [6][7][8][9][10] Of these 955 patients, 500 had CS IA and IIA.…”

Section: Clinical Stagingmentioning

confidence: 99%

“…The 219 patients with nonbulky CS IA or IIA received 3 cycles of either combination (ABVD, 113 patients; EBVM, 106 patients). 9,10 Finally, the 23 patients with bulky disease (characterized by an MMR Ն 0.45 or an infradiaphragmatic disease associating lumboaortic and pelvic nodes) were randomized to receive a multiagent CT including 7 drugs (plus methylprednisolone) delivered at the same cumulative dose over 3 months either in 3 courses (one every 4 weeks: arm Y, 14 patients) or in 4 courses (one every 3 weeks: arm Z, 9 patients). Radiation therapy given to CS IA and IIA Patients in both trials with complete remission (CR) or partial remission (PR) at completion of CT then underwent irradiation.…”

Section: Chemotherapies Given To Cs Ia and Iiamentioning

confidence: 99%

“…on April 29, 2019. by guest www.bloodjournal.org From associated with RT-induced lung fibrosis, 10 one each from pulmonary embolism, diabetic arteriopathy, and a car accident, and 2 from suicide).…”

Section: Rates Of Mortality In Crmentioning

confidence: 99%

“…In these trials, patients were treated by a brief chemotherapy (CT) followed by an extended-field radiotherapy (RT) regimen. [6][7][8][9][10] Among the 955 patients with HL at clinical stage (CS) IA to IVB recruited in these trials, 74 patients were initially classified as having lymphocyte predominance according to the Rye classification. The pathologic material (lymph node biopsies) of these 74 patients was centrally reviewed and LPHL (according to the REAL/WHO definitions) was found in 44 patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Feugier

2004

Blood

View full text Add to dashboard Cite

“…Patients were classified in CS IA to IVB according to the Ann Arbor criteria. [6][7][8][9][10] Of these 955 patients, 500 had CS IA and IIA.…”

Section: Clinical Stagingmentioning

confidence: 99%

Section: Chemotherapies Given To Cs Ia and Iiamentioning

confidence: 99%

Section: Rates Of Mortality In Crmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Feugier

2004

Blood

View full text Add to dashboard Cite

“…1,8 But, also, more aggressive regimens than ABVD with a presumably superior tumor control have been tested. However, both the EORTC H9-U and the GHSG HD11 studies failed to show a significant progression-free survival (PFS) advantage using the BEACOPP baseline regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone).…”

Section: Treatment Of Early Unfavorable Hlmentioning

confidence: 99%

The Past: What We Have Learned in the Last Decade

Borchmann

Engert

2010

Hematology

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) has become a curable malignancy for most patients during the last decades. However, many controversies still exist on the optimal strategy of how to cure our patients. The key question is how to balance the risks and toxicities of chemotherapy and radiotherapy against the need for a definite treatment for early or advanced-stage HL patients. However, although many studies have been conducted and reported during the past decade, interpretation of their results and treatment recommendations might vary significantly in different countries. For example, early-stage HL might be divided into two different subgroups: early favorable and early unfavorable or not. Treatment of early-stage HL might include radiotherapy ("combined modality") or not. Depending on the extent of radiotherapy, the schedule and number of chemotherapy cycles are also questioned. For advanced-stage HL, the situation is not much different. Compared with ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), the more aggressive escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) is highly effective, but also raises concern due to excessive toxicity. Thus, there is a controversy about the standard of care for advanced HL patients. Because no mature results comparing these approaches with each other are currently available, it remains our duty to share the preliminary information with our patients and to figure out the most appropriate individual treatment strategy. Of course, the discussion of these issues is influenced by experiences and preferences. In contrast, in this article, we will try to focus on the available scientific evidence regarding the first-line treatment of HL. Of course, focusing on the last decade necessarily exclude the most recent results from ongoing studies. Thus, even though this article comprises treatment recommendations for HL patients, the best treatment certainly still is within properly designed prospective clinical trials.

show abstract

Predictive and discriminating three‐risk‐group prognostic scoring system for staging Hodgkin lymphomas

Maucort-Boulch¹,

Djeridane²,

Roy³

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Several 3‐stage Ann Arbor classification‐derived prognostic systems were constructed since 1980 to identify the prognosis of Hodgkin lymphoma (HL). Modern statistical tools were applied to 955 patients treated between 1981 and 1996 to build a 3‐stage prognostic scoring system (PSS).METHODS.Each variable associated with 10‐year overall survival (10‐year OS) was assigned to 2 (0 or 1) or 3 (0, 1 or 3) values. By summing the values attributed to each variable, 3 stages were defined. 10‐year OS, 5‐year event‐free survival (5‐year EFS), and freedom from progression (5‐year FFP) rates of the PSS and of other existing systems were then compared.RESULTS.Four variables were associated with 10‐year OS: age (<40 = 0, ≥40 = 1), number of involved lymphoid areas (1–2 = 0, 3–4 = 1, ≥5 = 2), visceral disease (no = 0, yes = 1), and systemic symptoms (no = 0, yes = 1). Scores 0 and 1, 2 and 3, and ≥4 were attributed to 59.7%, 30.9%, and 9.4% of the patients who had 10‐year OS rates of 93.5, 75.7, and 53.4% and 5‐year EFS / 5‐year FFP rates of 91.2%/90.3%, 78.1%/76.3%, and 54.1%/52.6%, respectively. The discrimination and prediction abilities of the PSS were better than those of the other systems tested; moreover, the PSS adequately identified the few patients with a worse prognosis without resorting to the International Prognostic Score for advanced stages. The PSS was also highly predictive for 489 patients treated between 1997 and 2002.CONCLUSION.PSS is a useful alternative to the existing prognostic systems for evaluating HL patients. Cancer 2007. © 2006 American Cancer Society.

show abstract

Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial

Cited by 22 publications

References 50 publications

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

The Past: What We Have Learned in the Last Decade

Predictive and discriminating three‐risk‐group prognostic scoring system for staging Hodgkin lymphomas

Contact Info

Product

Resources

About